Total amount raised
$192 Millions
Latest funding date
06/01/2020
Location
Orca Bio has successfully raised significant funding over multiple rounds, focusing on developing high-precision cell therapies for cancer and autoimmune diseases. The company's innovative approach harnesses regulatory T cells to provide better outcomes with fewer risks.
Keep reading to explore the intricacies of Orca Bio's fundraising journey and the investors backing this pioneering biotechnology company.
What Is Orca Bio?
Orca Bio is a late-stage biotechnology company dedicated to developing high-precision cell therapies for cancer and autoimmune diseases. Their investigational allogeneic T-cell immunotherapies aim to harness the power of regulatory T cells to provide better outcomes with fewer risks for patients.
Committed to transforming cell therapy, Orca Bio focuses on expanding the life-changing benefits of these therapies. The company is driven by a mission to deliver the promise of cell therapy to patients without compromise.
How Much Funding Has Orca Bio Raised?
- Pre-Seed Round
- Amount Raised: Not publicly disclosed
- Date: May 2016
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To establish the company and begin initial research and development efforts.
- Series C
- Amount Raised: Not publicly disclosed
- Date: May 2018
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand research and development and advance clinical trials.
- Series D
- Amount Raised: $192M
- Date: June 2020
- Lead Investors: Lightspeed Venture Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To develop Orca Bio's pipeline of cell therapies and its manufacturing technology.
Total Amount Raised: $192M
Current Valuation: Not publicly disclosed
Key Investors
- Lightspeed Venture Partners
- Details: Lightspeed Venture Partners is a venture capital firm that focuses on early-stage investments in the technology sector. They have a strong track record of backing successful startups.
- Investment Focus Areas: Technology, enterprise, consumer, health sectors
- Notable Investments: Snapchat, GrubHub, Affirm
- 8VC
- Details: 8VC is a venture capital firm that invests in technology and healthcare companies. They aim to build and support transformative companies.
- Investment Focus Areas: Technology, healthcare, logistics, financial services
- Notable Investments: Palantir, Wish, Guardant Health
- DCVC Bio
- Details: DCVC Bio is a venture capital firm that focuses on deep tech investments, particularly in biotechnology and life sciences. They support companies that leverage advanced technologies to solve complex problems.
- Investment Focus Areas: Biotechnology, life sciences, healthcare
- Notable Investments: Zymergen, Recursion Pharmaceuticals, Pivot Bio
- Mubadala Investment Company
- Details: Mubadala Investment Company is a global investment firm based in Abu Dhabi. They manage a diverse portfolio across various sectors and geographies.
- Investment Focus Areas: Technology, healthcare, infrastructure
- Notable Investments: SoftBank Vision Fund, Cologix, Medallia
- Kaiser Foundation Hospitals
- Details: Kaiser Foundation Hospitals is part of the Kaiser Permanente healthcare system, which provides comprehensive health services to its members.
- Investment Focus Areas: Healthcare services, infrastructure
- Notable Investments: Not publicly disclosed
What's Next for Orca Bio?
Orca Bio stands at the cusp of a transformative era in cell therapy, with opportunities to revolutionize treatments for blood cancers, autoimmune diseases, and genetic disorders. Their high-precision allogeneic cell therapies, particularly TRGFT-201 and OGFT-001, promise to replace conventional bone marrow transplants, potentially reducing severe complications and improving patient outcomes.
As Orca Bio advances its clinical trials and refines its novel manufacturing platform, the company is well-positioned for future fundraising. Successful trial outcomes could attract further investments and strategic partnerships, enabling expansion into new therapeutic areas and markets. However, the path forward is not without challenges. Regulatory hurdles, high development costs, and competition from other biotech firms will test Orca Bio's resilience and innovation.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Orca Bio and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
